GZBL(SZ:002424) Zheng Quan Zhi Xing·2025-06-26 16:39Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. has addressed the issues raised in the 2023 internal control audit report, and the impact of the negative opinion has been eliminated, allowing the company to meet the conditions for the removal of risk warnings on its stock [3][4][6]. Group 1: Internal Control Audit Findings - The 2023 internal control audit report indicated significant deficiencies in the company's internal controls related to sales expenses, including delays in expense recognition and incomplete confirmations [6][9]. - The company has implemented a series of corrective measures to enhance internal controls and ensure compliance with relevant regulations [6][8]. Group 2: Compliance and Rectification Measures - The company has established a compliance management department and engaged third-party consulting firms to optimize internal controls and rectify deficiencies [7][8]. - Continuous training for relevant personnel has been emphasized to strengthen governance and prevent violations [8]. Group 3: Current Status and Future Outlook - As of December 31, 2024, the company maintained effective internal controls over financial reporting in all material respects [4][6]. - The company has confirmed that it does not meet any conditions that would require additional risk warnings under the Shenzhen Stock Exchange listing rules [5][6].